ULTRAGENYX PHARMACEUTICAL INC. Payments for (Proceeds from) Other Investing Activities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments for (Proceeds from) Other Investing Activities of $3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for the quarter ending 2026-06-30 was $3.00M.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was -$273.00K.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was $1.27M, a 527.09% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for fiscal 2025 was $1.00M, a 50.00% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for fiscal 2024 was $2.00M, a 66.67% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for fiscal 2023 was $6.00M, a 610.90% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. payments for (proceeds from) other investing activities for fiscal 2022 was $844.00K, a 10.40% decline from fiscal 2021.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 3 month as first filed | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 6 month as first filed | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month | Payments for (Proceeds from) Other Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 | $2.73M derived: sum of 3 quarters · filed 2026-08-05 | $4.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | -$273.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.00M derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.00M derived: sum of 2 quarters · filed 2026-02-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $1.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $273.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.27M 10-Q · filed 2025-11-05 | $964.00K derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $1.09M 10-Q · filed 2025-08-06 | -$309.00K derived: sum of 3 quarters · filed 2026-08-05 | -$106.00K derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $780.00K 10-Q · filed 2025-05-07 | $691.00K derived: sum of 2 quarters · filed 2026-05-06 | $894.00K derived: sum of 3 quarters · filed 2026-05-06 | $935.00K derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$106.00K derived: sum of 2 quarters · filed 2026-02-18 | -$65.00K derived: sum of 3 quarters · filed 2026-02-18 | $2.00M 10-K · filed 2026-02-18 | $2.44M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $244.00K derived: sum of 2 quarters · filed 2025-11-05 | $2.31M 10-Q · filed 2025-11-05 | $3.53M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.11M 10-Q · filed 2025-08-06 | $3.33M derived: sum of 3 quarters · filed 2026-02-18 | $3.76M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | $2.06M 10-Q · filed 2025-05-07 | $3.29M derived: sum of 2 quarters · filed 2026-02-18 | $3.72M derived: sum of 3 quarters · filed 2026-02-18 | $4.11M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.65M derived: sum of 2 quarters · filed 2026-02-18 | $2.05M derived: sum of 3 quarters · filed 2026-02-18 | $6.00M 10-K · filed 2026-02-18 | $5.05M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $428.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $826.00K derived: sum of 2 quarters · filed 2024-11-06 | $4.78M 10-Q · filed 2024-11-06 | $5.38M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $4.35M 10-Q · filed 2024-08-02 | $4.95M derived: sum of 3 quarters · filed 2025-02-19 | $5.13M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $3.95M 10-Q · filed 2024-05-03 | $4.55M derived: sum of 2 quarters · filed 2025-02-19 | $4.73M derived: sum of 3 quarters · filed 2025-02-19 | $4.92M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $781.00K derived: sum of 2 quarters · filed 2025-02-19 | $964.00K derived: sum of 3 quarters · filed 2025-02-19 | $844.00K 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $360.00K derived: sum of 2 quarters · filed 2023-11-03 | $240.00K 10-Q · filed 2023-11-03 | $695.00K derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $63.00K 10-Q · filed 2023-08-04 | $518.00K derived: sum of 3 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$120.00K 10-Q · filed 2023-05-05 | -$2.58M 10-Q · filed 2022-05-06 | $335.00K derived: sum of 2 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $942.00K 10-K · filed 2024-02-21 | |||||
| 2021-09-30 | $487.00K 10-Q · filed 2022-11-03 | ||||||
| 2020-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $5.55M 10-K · filed 2023-02-17 | |||||
| 2020-09-30 | $4.16M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |